Skip to main content

Advertisement

Table 1 The blood pressures, weights, and biochemistry data

From: The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats

  WKY (n = 9) SHR (n = 7) EMPA (n = 7) P value (ANOVA)
Body weight (g) 511.2 ± 26.8 452.0 ± 17.3a 420.9 ± 18.4bc < 0.0001
Heart weight (g) 1.92 ± 0.14 2.40 ± 0.43a 2.44 ± 0.26b 0.0029
Systolic pressure (mmHg) 80.7 ± 4.3 114.7 ± 3.8a 83.0 ± 2.7c 0.002
Diastolic pressure (mmHg) 47.0 ± 5.6 87.7 ± 5.3a 45.4 ± 3.6$ 0.002
  WKY (n = 5) SHR (n = 7) EMPA (n = 7) P value (ANOVA)
Fructosamine (µmol/L) 254.3 ± 66.9 155.2 ± 44.9a 144.6 ± 61.7b 0.0027
BUN (mg/dL) 12.9 ± 1.8 21.8 ± 1.6a 22.5 ± 4.8b 0.0002
Creatinine (mg/dL) 0.56 ± 0.07 0.59 ± 0.10 0.47 ± 0.07c 0.0519
AST (IU/L) 167.3 ± 52.5 190.0 ± 40.6 262.5 ± 138.6 0.1919
ALT (IU/L) 74.3 ± 68.4 174.2 ± 89.0 225.5 ± 194.3 0.1927
Uric acid (mg/dL) 1.79 ± 1.09 2.92 ± 0.82 2.39 ± 1.05 0.1731
Triglyceride (mg/dL) 79.8 ± 9.0 59.4 ± 6.7a 58.4 ± 7.3b 0.0003
Total cholesterol (mg/dL) 120.1 ± 10.0 64.6 ± 6.8a 64.6 ± 23.9b < 0.0001
LDL-C (mg/dL) 33.6 ± 4.9 18.7 ± 4.7a 17.1 ± 7.2b 0.0003
HDL-C (mg/dL) 90.7 ± 7.2 47.5 ± 4.3a 49.2 ± 21.2b < 0.0001
ANP (pg/mL) 82.8 ± 18.6 158.8 ± 69.1 93.8 ± 17.5 0.0659
  1. Data are presented as mean ± standard deviation
  2. With Tukey’s multiple comparison test
  3. aComparisons significant for SHR vs WKY
  4. bComparison significant for EMPA vs WKY
  5. cComparison significant for EMPA vs SHR